TY - JOUR AU - Szécsi, Balázs AU - Sinkó, Richárd AU - Vereb, Alexandra AU - Khochanskiy, Dmitry AU - Benke, Kálmán AU - Radovits, Tamás AU - Lakatos, Bálint AU - Kőszegi, Andrea AU - Losoncz, Eszter AU - Kugler, Szilvia AU - Szabó, Márk AU - Merkely, Béla Péter AU - Székely, Andrea AU - Gereben, Balázs TI - The perioperative period of heart transplantation is affected by thyroid hormone status JF - THYROID J2 - THYROID PY - 2024 SN - 1050-7256 DO - 10.1089/thy.2023.0628 UR - https://m2.mtmt.hu/api/publication/34801056 ID - 34801056 LA - English DB - MTMT ER - TY - JOUR AU - Roberto, Attanasio AU - Miloš, Žarković AU - Enrico, Papini AU - Nagy, Endre AU - Roberto, Negro AU - Petros, Perros AU - Ersin, Akarsu AU - Maria, Alevizaki AU - Göksun, Ayvaz AU - Tomasz, Bednarczuk AU - Biljana, Beleslin AU - Berta, Eszter AU - Bodor, Miklós AU - Anna, Maria Borissova AU - Mihail, Boyanov AU - Camille, Buffet AU - Maria-Cristina, Burlacu AU - Jasmina, Ciric AU - Juan, J. Díez AU - Harald, Dobnig AU - Valentin, V. Fadeyev AU - Benjamin, C. T. Field AU - Eric, Fliers AU - Dagmar, Führer AU - Juan, Carlos Galofré AU - Tommi, Hakala AU - Jan, Jiskra AU - Peter, A. Kopp AU - Michael, Krebs AU - Michal, Kršek AU - Martin, Kuzma AU - Mikael, Lantz AU - Ivica, Lazúrová AU - Laurence, Leenhardt AU - Vitaliy, Luchytskiy AU - Francisca, Marques Puga AU - Anne, McGowan AU - Saara, Metso AU - Carla, Moran AU - Tatyana, Morgunova AU - Dan, Alexandru Niculescu AU - Božidar, Perić AU - Tereza, Planck AU - Catalina, Poiana AU - Eyal, Robenshtok AU - Patrick, Olivier Rosselet AU - Marek, Ruchala AU - Kamilla, Ryom Riis AU - Alla, Shepelkevich AU - Mykola, D. Tronko AU - David, Unuane AU - Irfan, Vardarli AU - W., Edward Visser AU - Andromachi, Vryonidou AU - Younes, Ramazan Younes AU - Laszlo, Hegedus TI - Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists :$bThe "THESIS"* collaboration (*Treatment of Hypothyroidism in Europe by Specialists, an International Survey) JF - THYROID J2 - THYROID PY - 2024 SN - 1050-7256 UR - https://m2.mtmt.hu/api/publication/34747533 ID - 34747533 LA - English DB - MTMT ER - TY - JOUR AU - Bernardi, Stella AU - Rosolen, Valentina AU - Barbone, Fabio AU - Borgato, Stefano AU - Deandrea, Maurilio AU - De Feo, Pierpaolo AU - Fugazzola, Laura AU - Gambelunghe, Giovanni AU - Negro, Roberto AU - Oleandri, Salvatore AU - Papi, Giampaolo AU - Papini, Enrico AU - Retta, Francesca AU - Rossetto, Ruth AU - Sansone, Daniela AU - Serra, Giuseppe AU - Sconfienza, Luca Maria AU - Solbiati, Luigi AU - Spiezia, Stefano AU - Stacul, Fulvio AU - Mauri, Giovanni TI - Clinical Outcomes of Thermal Ablation Re-Treatment of Benign Thyroid Nodules: A Multicenter Study from the Italian Minimally Invasive Treatments of the Thyroid Group JF - THYROID J2 - THYROID PY - 2024 PG - 11 SN - 1050-7256 DO - 10.1089/thy.2023.0501 UR - https://m2.mtmt.hu/api/publication/34680786 ID - 34680786 LA - English DB - MTMT ER - TY - JOUR AU - Kaplan, Zoe B. AU - Pearce, Elizabeth N. AU - Lee, Sun Y. AU - Shin, Hyeong-Moo AU - Schmidt, Rebecca J. TI - Maternal Thyroid Dysfunction During Pregnancy as an Etiologic Factor in Autism Spectrum Disorder: Challenges and Opportunities for Research JF - THYROID J2 - THYROID PY - 2024 PG - 14 SN - 1050-7256 DO - 10.1089/thy.2023.0391 UR - https://m2.mtmt.hu/api/publication/34646748 ID - 34646748 LA - English DB - MTMT ER - TY - JOUR AU - Cavallo, Andrea Camila AU - Pitoia, Fabian AU - Roberti, Javier AU - Brenzoni, Pablo AU - Lencioni, Melisa AU - Jaroslavsky, Maria Jose AU - Spengler, Eunice AU - Voogd, Ana AU - Firpo, Claudia AU - Saco, Pedro AU - Pinero, Federico AU - Negueruela, Maria TI - Optimizing Diagnostic Accuracy of Fine Needle Aspiration Biopsy Calcitonin Measurements in Detecting Medullary Thyroid Carcinoma JF - THYROID J2 - THYROID PY - 2024 PG - 11 SN - 1050-7256 DO - 10.1089/thy.2023.0313 UR - https://m2.mtmt.hu/api/publication/34598486 ID - 34598486 N1 - Export Date: 28 February 2024; CODEN: THYRE AB - Background: The optimal cutoff value of calcitonin (Ctn) levels measured using an electrochemiluminescence immunoassay (ECLIA) obtained from the washout fluid of fine needle aspiration (FNA-Ctn) for the diagnosis of medullary thyroid carcinoma (MTC) is currently not established. We evaluated the diagnostic accuracy and clinical utility of FNA-Ctn for the diagnosis and location of MTC in patients with nodular or multinodular goiters. Methods: This was a case-control study nested on a prospective multicenter cohort of patients with nodular or multinodular goiter, normal or elevated serum Ctn, and thyroidectomy indications. Ctn and FNA-Ctn were measured using ECLIA methodology before surgery. From this nested cohort, MTC cases and controls (non-medullary pathology) were identified from the final pathological analysis. Cumulative incidence sampling of controls was randomly performed at a ratio of 1:2. Sensitivity, specificity, and area under the receiver operator curve (AUROC) were calculated for patients and the total number of thyroid nodules. Results: From 1272 patients included in the prospective cohort, 50 MTC cases and 105 controls were included. In this study, 286 thyroid nodules were evaluated (63 MTC and 223 non-MTCs). The median serum Ctn value was significantly higher in cases (525 pg/mL [interquartile range (IQR), 162.5-1.200]) than in controls (1.6 pg/mL [IQR, 0.5-5.6]; p < 0.001). The median FNA-Ctn value was significantly higher in MTC nodules (3.100 pg/mL [IQR, 450-45,200]) than in non-MTC nodules (0.5 pg/mL [IQR, 0.5-0.5]; p < 0.0001). In 11 MTC patients with multinodular goiter, the FNA-Ctn value was significantly higher in non-medullary nodules located in the same lobe where an MTC nodule was diagnosed (p = 0.0002). Overall, the FNA-Ctn AUROC was 0.99 [95% confidence interval, 0.98-1.0], and a threshold of >= 220 pg/mL showed 100% sensitivity and 98% specificity for MTC diagnosis. Conclusions: The use of FNA-Ctn measured by ECLIA showed adequate diagnostic accuracy for MTC diagnosis. Moreover, it may be clinically useful for localization in multinodular goiter when lobectomy is considered. LA - English DB - MTMT ER - TY - JOUR AU - Chandrasekar, Akila AU - Schmidtlein, Paula Marie AU - Neve, Vanessa AU - Rivagorda, Manon AU - Spiecker, Frauke AU - Gauthier, Karine AU - Prevot, Vincent AU - Schwaninger, Markus AU - Mueller-Fielitz, Helge TI - Regulation of Thyroid Hormone Gatekeepers by Thyrotropin in Tanycytes JF - THYROID J2 - THYROID PY - 2024 PG - 13 SN - 1050-7256 DO - 10.1089/thy.2023.0375 UR - https://m2.mtmt.hu/api/publication/34578010 ID - 34578010 N1 - Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain Behavior and Metabolism (CBBM), University of Lübeck, Lübeck, Germany ENS de Lyon, INRAE, CNRS, Institut de Génomique Fonctionnelle de Lyon, University of Lyon, Lyon, France Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S 1172, European Genomic Institute for Diabetes (EGID), University of Lille, Lille, France DZHK (German Research Centre for Cardiovascular Research), Hamburg-Lübeck-Kiel, Lübeck, Germany Cited By :1 Export Date: 27 March 2024 CODEN: THYRE Correspondence Address: Müller-Fielitz, H.; Institute for Experimental and Clinical Pharmacology and Toxicology, Ratzeburger Allee 160, Germany; email: helge.muellerfielitz@uni-luebeck.de Chemicals/CAS: cyclic AMP, 60-92-4; mitogen activated protein kinase, 142243-02-5; protein kinase C, 141436-78-4; protein kinase C theta; serine threonine protein kinase D2; thyrotropin, 9002-71-5; thyroxine deiodinase, 70712-46-8; Pituitary Hormone-Releasing Hormones; Protein Kinase C; Receptors, Thyrotropin; Thyroid Hormones; Thyrotropin Funding details: European Research Council, ERC Funding details: Deutsche Forschungsgemeinschaft, DFG, P01, Project-ID 424957847-CRC/TRR296 Funding text 1: H.M.-F. received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; Project-ID 424957847-CRC/TRR296, P02); M.S. received funding from the Deutsche Forschungsgemeinschaft (Project-ID 424957847-CRC/TRR296, P01) and from the European Research Council (ERC) Synergy Grant-2019-WATCH-810331; V.P. received support from the ERC Synergy Grant-2019-WATCH-810331; all other authors received no additional support, which were used for this work. AB - Background: Tanycytes are specialized glial cells within the mediobasal hypothalamus that have multiple functions, including hormone sensing and regulation of hypophysiotropic hormone secretion. There are ongoing discussions about the role of tanycytes in regulating the supply of hypothalamic thyroid hormones (THs) through the expression of TH transporters (Slc16a2, Slco1c1) and deiodinases (Dio2, Dio3). In this study, we investigated the potential feedback effect of thyrotropin (TSH) on the transcription of these gatekeeper genes on tanycytes.Methods: We analyzed the changes in the expression of TH-gatekeeper genes, in TSH-stimulated primary tanycytes, using quantitative polymerase chain reaction (qPCR). We also used RNAScope (R) in brain slices to further reveal the local distribution of the transcripts. In addition, we blocked intracellular pathways and used small-interfering RNA (siRNA) to elucidate differences in the regulation of the gatekeeper genes.Results: TSH elevated messenger RNA (mRNA) levels of Slco1c1, Dio2, and Dio3 in tanycytes, while Slc16a2 was mostly unaffected. Blockade and knockdown of the TSH receptor (TSHR) and antagonization of cAMP response element-binding protein (CREB) clearly abolished the increased expression induced by TSH, indicating PKA-dependent regulation through the TSHR. The TSH-dependent expression of Dio3 and Slco1c1 was also regulated by protein kinase C (PKC), and in case of Dio3, also by extracellular signal-regulated kinase (ERK) activity. Importantly, these gene regulations were specifically found in different subpopulations of tanycytes.Conclusions: This study demonstrates that TSH induces transcriptional regulation of TH-gatekeeper genes in tanycytes through the Tshr/G alpha q/PKC pathway, in parallel to the Tshr/G alpha s/PKA/CREB pathway. These differential actions of TSH on tanycytic subpopulations appear to be important for coordinating the supply of TH to the hypothalamus and aid its functions. LA - English DB - MTMT ER - TY - JOUR AU - Capdevila, Jaume AU - Krajewska, Jolanta AU - Hernando, Jorge AU - Robinson, Bruce AU - Sherman, Steven I AU - Jarzab, Barbara AU - Lin, Chia-Chi AU - Vaisman, Fernanda AU - Hoff, Ana O AU - Hitre, Erika AU - Bowles, Daniel W AU - Williamson, Denise AU - Levytskyy, Roman AU - Oliver, Jennifer AU - Keam, Bhumsuk AU - Brose, Marcia S TI - Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology. A Subgroup Analysis of the COSMIC-311 Study. TS - A Subgroup Analysis of the COSMIC-311 Study. JF - THYROID J2 - THYROID VL - 34 PY - 2024 IS - 3 SP - 347 EP - 359 PG - 13 SN - 1050-7256 DO - 10.1089/thy.2023.0463 UR - https://m2.mtmt.hu/api/publication/34558160 ID - 34558160 AB - Background: Lenvatinib and sorafenib are standard of care first-line treatments for advanced, radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC). However, most patients eventually become treatment-resistant and require additional therapies. The phase 3 COSMIC-311 study investigated cabozantinib in patients with RAIR DTC who progressed on lenvatinib, sorafenib, or both and showed that cabozantinib provided substantial clinical benefit. Presented in this study is an analysis of COSMIC-311 based on prior therapy and histology. Methods: Patients were randomized 2:1 (stratification: prior lenvatinib [yes/no]; age [≤65, >65 years]) to oral cabozantinib (60 mg tablet/day) or matched placebo. Eligible patients received 1-2 prior vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors for DTC (lenvatinib or sorafenib required), had a confirmed DTC diagnosis, and were refractory to or ineligible for radioiodine therapy. For this analysis, progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 by a blinded independent radiology committee were evaluated by prior therapy (lenvatinib only, sorafenib only, both) and histology (papillary, follicular, oncocytic, poorly differentiated). Results: Two hundred fifty-eight patients were randomized (170 cabozantinib/88 placebo) who previously received sorafenib only (n = 96), lenvatinib only (n = 102), or both (n = 60). The median follow-up was 10.1 months. The median PFS (months) with cabozantinib/placebo was 16.6/3.2 (sorafenib only: hazard ratio [HR] 0.13 [95% confidence interval, CI, 0.06-0.26]), 5.8/1.9 (lenvatinib only: HR 0.28 [95% CI 0.16-0.48]), and 7.6/1.9 (both: HR 0.27 [95% CI 0.13-0.54]). The ORR with cabozantinib/placebo was 21%/0% (sorafenib only), 4%/0% (lenvatinib only), and 8%/0% (both). Disease histology consisted of 150 papillary and 113 follicular, including 43 oncocytic and 36 poorly differentiated. The median PFS (months) with cabozantinib/placebo was 9.2/1.9 (papillary: HR 0.27 [95% CI 0.17-0.43]), 11.2/2.5 (follicular: HR 0.18 [95% CI 0.10-0.31]), 11.2/2.5 (oncocytic: HR 0.06 [95% CI 0.02-0.21]), and 7.4/1.8 (poorly differentiated: HR 0.18 [95% CI 0.08-0.43]). The ORR with cabozantinib/placebo was 15%/0% (papillary), 8%/0% (follicular), 11%/0% (oncocytic), and 9%/0% (poorly differentiated). Safety outcomes evaluated were consistent with those previously observed for the overall population. Conclusions: Results indicate that cabozantinib benefits patients with RAIR DTC, regardless of prior lenvatinib or sorafenib treatments or histology. Clinical Trial Registration Number: NCT03690388. LA - English DB - MTMT ER - TY - JOUR AU - Milanesi, A. AU - Brent, G.A. TI - Weighing in on Thyroid Signaling in the Hypothalamus: Mechanisms and Interface with Metabolic Regulators JF - THYROID J2 - THYROID VL - 34 PY - 2024 IS - 2 SP - 141 EP - 143 PG - 3 SN - 1050-7256 DO - 10.1089/thy.2024.0031 UR - https://m2.mtmt.hu/api/publication/34751104 ID - 34751104 N1 - Export Date: 21 March 2024 CODEN: THYRE Correspondence Address: Brent, G.A.; Division of Endocrinology Diabetes and Metabolism, 10833 Le Conte Avenue, United States; email: gbrent@mednet.ucla.edu Chemicals/CAS: 3,3',5' triiodothyronine, 5817-39-0, 70-39-3; cyclic AMP responsive element binding protein, 130428-87-4, 130939-96-7; glucagon like peptide 1, 89750-14-1; liothyronine, 6138-47-2, 6893-02-3; neuropeptide Y, 82785-45-3, 83589-17-7; protirelin, 24305-27-9; thyrotropin, 9002-71-5; thyroxine, 7488-70-2; thyroxine deiodinase, 70712-46-8 Funding details: U.S. Department of Veterans Affairs, VA, 01BX001966, 01BX006245 Funding text 1: This study was funded by Grant Support VA Merit Award 01BX006245 (A.M.) and VA Merit Award 01BX001966 (G.A.B.). LA - English DB - MTMT ER - TY - JOUR AU - Ruska, Yvette Magdolna AU - Péterfi, Zoltán Attila AU - Stiftné Szilvásy-Szabó, Anett AU - Kővári, Dóra AU - Hrabovszky, Erik AU - Dorogházi, Beáta Vanessza AU - Gereben, Balázs AU - Tóth, Blanka AU - Matziari, Magdalini AU - Wittmann, Gábor AU - Fekete, Csaba TI - GLP-1 Receptor Signaling Has Different Effects on the Perikarya and Axons of the Hypophysiotropic Thyrotropin-Releasing Hormone Synthesizing Neurons in Male Mice JF - THYROID J2 - THYROID VL - 34 PY - 2024 IS - 2 SP - 252 EP - 260 PG - 9 SN - 1050-7256 DO - 10.1089/thy.2023.0284 UR - https://m2.mtmt.hu/api/publication/34578220 ID - 34578220 AB - Background: Glucagon-like peptide 1 (GLP-1) is involved in the regulation of energy and glucose homeostasis. As GLP-1 has similar effects on the energy homeostasis as the hypophysiotropic thyrotropin-releasing hormone (TRH) neurons that regulate the hypothalamic-pituitary-thyroid (HPT) axis, we raised the possibility that the TRH neurons are involved in the mediation of the effects of GLP-1. Therefore, the relationship and interaction of the GLP-1 system and the TRH neurons of the hypothalamic paraventricular nucleus (PVN) were studied.Methods: To examine the anatomical and functional relationship of TRH neurons and the GLP-1 system in the PVN, immunocytochemistry, in situ hybridization, in vitro patch-clamp electrophysiology, metabolic phenotyping, and explant experiments were performed.Results: Our data demonstrate that the TRH neurons of the PVN are innervated by GLP-1 producing neurons and express the GLP-1 receptor (GLP-1R). However, not only do the GLP-1-innervated TRH neurons express GLP-1R but the receptor is also present in the axons of the hypophysiotropic TRH neurons in the blood-brain barrier free median eminence (ME) suggesting that peripherally derived GLP-1 may also influence the TRH neurons. In vitro, GLP-1 increased the firing rate of TRH neurons and depolarized them. In addition, GLP-1 directly stimulated the GABAergic input of a population of TRH neurons. Furthermore, GLP-1 inhibited the release of TRH from the hypophysiotropic axons in the ME. In vivo, peripheral GLP-1R agonist administration markedly inhibited the food intake and the energy expenditure, but had no effect on the TRH expression in the PVN and resulted in lower circulating free T4 levels.Conclusions: Our results indicate that GLP-1R activation has a direct stimulatory effect on TRH neurons in the PVN, but the activation of GLP-1R may also inhibit TRH neurons by facilitating their inhibitory inputs or by inhibiting the axon terminals of these cells in the ME. The innervation of TRH neurons by GLP-1 neurons suggests that TRH neurons might be influenced by both circulating GLP-1 and by GLP-1 neurons of the nucleus tractus solitarii. The lack of GLP-1R agonist-induced regulation of TRH neurons in vivo suggests that the HPT axis does not mediate the GLP-1R agonist-induced weight loss. LA - English DB - MTMT ER - TY - JOUR AU - Goldner, Whitney AU - Sinclair, Catherine TI - Clinical and Surgical Year in Review JF - THYROID J2 - THYROID VL - 34 PY - 2024 IS - 1 SP - 3 EP - 9 PG - 7 SN - 1050-7256 DO - 10.1089/thy.2023.0601 UR - https://m2.mtmt.hu/api/publication/34672491 ID - 34672491 LA - English DB - MTMT ER -